Clinical Trial VICCMD1188


An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Principal Investigator(s)

Igor Puzanov


  • Protocol No. VICCMD1188
  • Open Date: 06/08/2012
  • Staging: Phase II
  • Age Group: Adults
  • Scope: International
  • Objective: To evaluate the efficacy of vemurafenib in patients with cancers harboring BRAF V600 mutations as response rate (RR) at Week 8 determined by the Investigator using Response Evaluation Criteria In Solid Tumors, Version 1.1 (RECIST, v1.1) or International Myeloma Working Group (IMWG) uniform response criteria and to identify tumor types for further development
  • Disease Sites: Breast; Head/Neck; Sarcoma; Gynecologic; Dermatologic; Prostate; Bladder; Kidney (Renal Cell); Ovarian; Pancreatic; Cervical; Esophageal; Colon; Rectal; Adrenocortical; Liver; Lung; Uterine; Small Cell; Multiple Myeloma; GIST; Gastric/Gastroesophageal; Neuroendocrine
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cetuximab; Cetuximab (Erbitux); PLX4032; RO5185426 (Vemurafenib); Vemurafenib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01524978
  • Secondary Protocol No: MO28072



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.